Naibec Discusses Anticancer Inhibitor Therapy Technology Transfer at Bio USA... "Tumor Size Reduced by 90%"

Published 08 Jun.2021 13:58(KST)

[Asia Economy Reporter Hyungsoo Park] Naivek, a peptide fusion specialist company, announced on the 8th that it will participate in the world's largest bio exhibition and conference, the '2021 BIO International Convention (BIO USA),' held from the 10th.

At BIO USA, Naivek plans to hold corporate partnering discussions with global big pharma companies regarding its major pipelines, including the peptide-based 'KRAS anticancer inhibitor therapy' under development, as well as 'pulmonary fibrosis treatment' and 'inflammatory bowel disease treatment.'

Through the research status presentation section, Naivek will also present preclinical efficacy results of various spectrum KRAS inhibitors, including small molecule anticancer drugs, and research results on drug delivery nanoparticles such as messenger ribonucleic acid (mRNA) and short interfering ribonucleic acid (siRNA).

Naivek is expected to attract significant attention from many pharmaceutical companies by presenting the final research results of mouse experiments (syngeneic animal models) on the 'KRAS anticancer inhibitor therapy,' which is the first to introduce a drug delivery system at BIO USA.

The KRAS anticancer inhibitor therapy is a targeted anticancer drug developed by Naivek based on the 'KRAS inhibitor.' It applies the drug delivery platform 'NIPEP-TPP,' which has selective targeting functions for cells and tissues. Research is underway to determine its applicability to various cancer types, including lung cancer and prostate cancer, in addition to colorectal cancer.

Naivek recently conducted mouse experiments on the KRAS anticancer inhibitor therapy. The tumor size in the treated experimental group decreased by 90% compared to the control group, and lifespan was extended by 40 days. Significant results were also confirmed in a colorectal cancer syngeneic tumor animal model combined with 'siRNA,' where tumor size decreased by 87%.

In addition to the KRAS anticancer inhibitor therapy, Naivek plans to hold meetings through corporate partnering for the peptide-based 'fibrosis treatment (NIPEP-PF)' and 'inflammatory bowel disease treatment (NIPEP-IBD).'

Naivek's inflammatory bowel disease treatment is being jointly researched with the UK-based Intract Pharma. The oral formulation's drug delivery efficacy has been verified. Naivek aims to enter Phase 1 clinical trials for the pulmonary fibrosis treatment and inflammatory bowel disease treatment early next year.

A Naivek official stated, "BIO USA is the world's largest bio conference, and Naivek plans to review progress and share the current status with global big pharma companies with whom discussions have been ongoing," adding, "We also plan to hold meetings regarding Naivek's pipelines with pharmaceutical companies and biotechs expressing interest."

He continued, "Since we will present research results on the KRAS anticancer therapy and mRNA, which have recently attracted much attention domestically and internationally, meetings have been scheduled with various biotechs, including global big pharma, expressing interest."